Lázár L, Fülöp F
Szent-Györgyi Albert Orvostudományi Egyetem, Gyógyszerkémiai Intézet, Szeged.
Acta Pharm Hung. 1999 Sep;69(4):202-7.
Many unfavourable pharmacological and physicochemical properties of drugs can be improved by the application of prodrugs. Ring-chain tautomeric prodrugs include 1,3-X,N-heterocycles prepared from dysfunctional compounds with aldehydes or ketones. From the ring-chain equilibria of these derivatives, the open form undergoes continuous hydrolysis to give the bioactive molecule, which can be either the original dysfunctional compound or an oxo compound. This concept was applied in cases of oxazolidine and thiazolidine prodrugs derived from (-)-ephedrine, L-cysteine and hydrocortisone. From studies on 2-aryl-1,3-X,N-heterocycles, it has been unequivocally concluded that ring-chain tautomerism is characteristic not only for 1,3-O, N-heterocycles, but also for their 1,3-S,N- and 1,3-N,N-analogues. The ratios of the tautomeric forms involved in the equilibria of these systems are strongly influenced by the steric and electronic characters of the substituents. The results demonstrate that the transformation of a drug candidate to a ring-chain tautomeric prodrug is always worthy of consideration, when the pharmacologically active compound contains a 1,2- or 1,3-amino alcohol, a diamine or an amino thiol moiety or an oxo group.
通过应用前药,可以改善药物许多不利的药理和物理化学性质。环链互变异构前药包括由带有醛或酮的功能失调化合物制备的1,3 - X,N - 杂环。从这些衍生物的环链平衡来看,开环形式会持续水解生成生物活性分子,该生物活性分子可以是原始的功能失调化合物或氧代化合物。这一概念已应用于源自(-)-麻黄碱、L - 半胱氨酸和氢化可的松的恶唑烷和噻唑烷前药的情况。通过对2 - 芳基 - 1,3 - X,N - 杂环的研究,已明确得出结论,环链互变异构不仅是1,3 - O,N - 杂环的特征,也是其1,3 - S,N - 和1,3 - N,N - 类似物的特征。这些体系平衡中涉及的互变异构形式的比例受到取代基的空间和电子特性的强烈影响。结果表明,当药理活性化合物含有1,2 - 或1,3 - 氨基醇、二胺或氨基硫醇部分或氧代基团时,将候选药物转化为环链互变异构前药总是值得考虑的。